Weak Result Stops Pfizer’s Tremelimumab Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.
You may also be interested in...
Intermediate Endpoint Proposals For Cancer Immunotherapies Don’t Sway FDA
An issue brief laying out four potential intermediate endpoints for checkpoint modulators draws a cautious response from FDA representatives at a cancer research conference. The endpoints may prove useful for exploratory purposes but are far from ready to serve as the basis for registration, agency says.
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.
Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.